Gln→Arg 191 polymorphism of paraoxonase and Parkinson's disease

Human Heredity

Volumn 49, Issue 3, 1999, Pages 178-180

  Akhmedova, S ^a   Anisimov, S ^a   Yakimovsky, A ^b   Schwartz, Eugene ^a  

^a PETERSBURG NUCLEAR PHYSICS INSTITUTE   (Russian Federation)

^b PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Organophosphates; Paraxonase; Parkinson's disease

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ORGANOPHOSPHATE; ARGININE; DNA; ESTERASE; GLUTAMINE; PON1 PROTEIN, HUMAN; RESTRICTION ENDONUCLEASE; TYPE I SITE SPECIFIC DEOXYRIBONUCLEASE;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; PARKINSON DISEASE; TREMOR; ALLELE; ENZYMOLOGY; GENE FREQUENCY; GENETICS; METABOLISM; MIDDLE AGED; NUCLEOTIDE SEQUENCE;

AGED; ALLELES; AMINO ACID SUBSTITUTION; ARGININE; ARYLDIALKYLPHOSPHATASE; BASE SEQUENCE; DEOXYRIBONUCLEASES, TYPE I SITE-SPECIFIC; DNA; DNA RESTRICTION ENZYMES; ESTERASES; GENE FREQUENCY; GENOTYPE; GLUTAMINE; HUMANS; MIDDLE AGED; PARKINSON DISEASE; POLYMORPHISM, GENETIC;

EID: 0032587920     PISSN: 00015652     EISSN: None     Source Type: Journal    
DOI: 10.1159/000022868     Document Type: Article

References (13)

1. Mizuno Y, Ikebe S, Hattori N, Nakagawa-Hattori Y, Mochizuki H, Tanaka M, Ozawa T: Role of mitochondria in the etiology and pathogenesis of Parkinson's disease. Biochim Biophys Acta 1995;1271:265-274.
2. Golbe LI: Risk factors in young-onset Parkinson's disease. Neurology 1993;43:1641-1643.
3. Ben-Sholomo Y: How far are we in understanding the cause of Parkinson's disease? J Neurol Neurosurg Psychiatry 1996;61:4-16.
4. Liou HH, Tsai MC, Chen CJ, Jeng JS, Chang YC, Chen SY, Chen RC: Environmental risk factors and Parkinson's disease. Neurology 1997;48:1583-1588.
5. Seidler A, Hellenbrand W, Robra BP, Vieregge P, Nischan P, Joerg J, Oertel WH, Ulm G, Schneider E: Possible environmental, occupational, and other etiological factors for Parkinson's disease. Neurology 1997;46:1275-1284.
6. Hubble JP, Cao T, Hassanein RES, Neuberger JS, Koller WC: Risk factors for Parkinson's disease. Neurology 1993;43:1693-1697.
7. Adkins S, Gan KN, Mody M, La Du BN: Molecular basis for the polymorphic forms of human serum paraoxonase/arylestarase: Glutamate or arginine at position 191, for the respective A or B allozyms. Am J Hum Genet 1993; 52:598-608.
8. Hoehn MM, Yahr MD: Parkinsonism, onset, progression and mortality. Neurology 1967; 17: 427-442.
9. Humbert R, Adler DA, Disteche CD, Hassett C, Omiecinski CJ, Furlong CE: The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993;3:73-76.
10. Costa LG, McDonald BE, Murphy SD, Omenn GS, Richter RJ, Motulsky AG, Furlong CE: Serum paraoxonase and its influence on paraoxon and chorpyrifos oxon toxicity in rats. Toxicol Appl Pharmacol 1990; 103:66-69.
11. Logroscino G, Marder K, Cote L, Tang MX, Shea S, Mayeux R: Dietary lipids and antioxidants in Parkinson's disease: A population-based, case-control study. Ann Neurol 1996;39: 89-94.
12. Jenner P: Oxidative damage in neurodegenerative disease. Lancet 1994;344:796-798.
13. Ruiz J, Blanche H, James RW, Garin MB, Vaisse C, Charpentier G, Cohen N, Morabia A, Passa P, Froguel P: Gln-Arg 192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 1995;346:869-872.